Newsroom

Newsroom

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

October 4, 2021

Agreement adds cutting-edge innovation to Galderma’s aesthetic injectable portfolio, the aesthetic industry’s broadest injectable range

October 4 2021

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

Agreement adds cutting-edge innovation to Galderma’s aesthetic injectable portfolio, the aesthetic industry’s broadest injectable range

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

October 4, 2021

RESTYLANE® EYELIGHT™ to launch as new targeted treatment solution for under-eye shadows 

October 4 2021

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

RESTYLANE® EYELIGHT™ to launch as new targeted treatment solution for under-eye shadows 

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

October 4, 2021

Data supporting the positive decision demonstrated that patients treated with Alluzience® for wrinkles had a rapid onset of effect starti

October 4 2021

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

Data supporting the positive decision demonstrated that patients treated with Alluzience® for wrinkles had a rapid onset of effect starti

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

October 4, 2021

Cécile Dussart discusses ESG being an integral part of Galderma's business

October 4 2021

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

Cécile Dussart discusses ESG being an integral part of Galderma's business

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

October 4, 2021

The unsurpassed NASHA™ technology, which is still used today as the benchmark for fillers, was pioneered by Galderma

October 4 2021

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

The unsurpassed NASHA™ technology, which is still used today as the benchmark for fillers, was pioneered by Galderma

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe

March 23, 2021

Updated administration protocol means Sculptra® offers the fastest reconstitution of any injectable PLLA available in Europe.

March 23 2021

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe

Updated administration protocol means Sculptra® offers the fastest reconstitution of any injectable PLLA available in Europe.

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

March 23, 2021

Represents second approved indication for Restylane® DEFYNE™ in U.S. 

March 23 2021

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

Represents second approved indication for Restylane® DEFYNE™ in U.S. 

Galderma launches Dysport® in China for treatment of glabellar lines

November 19, 2020

Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.

November 19 2020

Galderma launches Dysport® in China for treatment of glabellar lines

Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

November 19, 2020

Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®.

November 19 2020

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®.